Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bright Minds Biosciences Inc (DRUG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: DRUG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $94.81
1 Year Target Price $94.81
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1755.76% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 172.77M USD | Price to earnings Ratio - | 1Y Target Price 94.81 |
Price to earnings Ratio - | 1Y Target Price 94.81 | ||
Volume (30-day avg) 6 | Beta 0.45 | 52 Weeks Range 0.93 - 79.02 | Updated Date 06/29/2025 |
52 Weeks Range 0.93 - 79.02 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -10.57% | Return on Equity (TTM) -11.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 133275414 | Price to Sales(TTM) - |
Enterprise Value 133275414 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 7083240 | Shares Floating 2983319 |
Shares Outstanding 7083240 | Shares Floating 2983319 | ||
Percent Insiders 22.55 | Percent Institutions 74.12 |
Analyst Ratings
Rating 3 | Target Price 94.81 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bright Minds Biosciences Inc
Company Overview
History and Background
Bright Minds Biosciences Inc. is a biotechnology company focused on developing novel drugs for the treatment of neuropsychiatric disorders, epilepsy, and pain. Founded in 2017, they have focused on developing selective 5-HT2C agonists. They went public via reverse merger in 2020.
Core Business Areas
- Drug Development: Focuses on developing novel therapies for treating various central nervous system (CNS) disorders.
Leadership and Structure
The leadership team consists of seasoned biotechnology executives and scientists. The organizational structure is typical of a biotech company with research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- BMB-101: A selective 5-HT2C agonist being developed for Dravet syndrome. It is in clinical trials. Competitors include existing anti-epileptic drugs from companies like GW Pharmaceuticals (now Jazz Pharmaceuticals) (JAZZ) and others developing novel therapies.
- BMB-202: A selective 5-HT2C agonist being developed for treatment resistant depression. It is in preclinical stages. Competitors include SSRIs, SNRIs, and novel therapies developed by companies like Axsome Therapeutics (AXSM).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the CNS therapeutic area, is characterized by high R&D costs, stringent regulatory requirements, and a significant unmet medical need. There is increasing interest in novel therapies for epilepsy, depression, and pain.
Positioning
Bright Minds is positioned as a drug discovery and development company focused on specific 5-HT2C receptor targets. Their competitive advantage lies in their selective agonists.
Total Addressable Market (TAM)
The TAM for CNS therapeutics is estimated to be hundreds of billions of dollars. Bright Minds is targeting specific subsegments within that TAM such as Dravet Syndrome and Treatment Resistant Depression, which represent significant market opportunities.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting 5-HT2C receptor
- Experienced leadership team
- Focus on unmet medical needs
Weaknesses
- Early-stage drug development
- Limited financial resources
- Dependence on successful clinical trials
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- Jazz Pharmaceuticals (JAZZ)
- Axsome Therapeutics (AXSM)
Competitive Landscape
Bright Minds faces competition from established pharmaceutical companies with greater resources and experience. Their advantage lies in their novel drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on advancing drug candidates through clinical trials.
Future Projections: Future growth depends on the success of their clinical programs and potential partnerships.
Recent Initiatives: Advancing BMB-101 into later-stage clinical trials; preclinical research on BMB-202.
Summary
Bright Minds Biosciences is an early-stage biotech company focused on developing novel CNS therapies. Success hinges on positive clinical trial outcomes and securing partnerships. The company faces significant risks related to drug development and competition from larger pharmaceutical firms. Funding and cash management are crucial for their survival and progress. Their novel approach, if successful, could be a major strength.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share figures are estimates based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com | ||
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.